Pricing Log in Create free account

Actuate Therapeutics, Inc. (ACTU) vs Moleculin Biotech, Inc. (MBRX)

Actuate Therapeutics, Inc. and Moleculin Biotech, Inc. are both Biotechnology companies. Actuate Therapeutics, Inc. is the larger, with a market value of $18.0M against $9.2M — 2.0× the size. Actuate Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Moleculin Biotech, Inc. trades at 0.0×. Across the 9 metrics below, Moleculin Biotech, Inc. leads on 5 and Actuate Therapeutics, Inc. on 4.

Valuation

Metric ACTU MBRX Biotechnology median
P/E n/m 0.04 10.26
P/S n/m n/m 9.18
P/B 8.21 0.21 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA n/m 0.16 0.65
EV/Sales n/m n/m 8.98
Earnings yield (255.88%) 2,573.95% (34.89%)
Free cash flow yield (244.40%) (1,027.71%) (24.52%)

Profitability

Metric ACTU MBRX Biotechnology median
Gross margin — 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 2,457.65% (1,471.05%) (50.12%)
Return on assets (336.18%) (152.41%) (45.60%)
Return on invested capital 0.00% (417.27%) 0.00%

Growth

Metric ACTU MBRX Biotechnology median
Revenue growth (TTM) — — 6.26%
EPS growth (last fiscal year) 67.48% 82.01% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric ACTU MBRX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 1.25 0.94 4.89
Net debt to EBITDA 0.59 0.35 1.01

Dividend

Metric ACTU MBRX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ACTU MBRX Biotechnology median
Market cap 17.98m 9.16m 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack